The merger between Klaria and Karessa has been completed
The Swedish Companies Registration Office (the “SCRO”) has today registered the merger between Klaria Pharma Holding AB (publ) (”Klaria”) (Nasdaq First North Growth Market: KLAR) and Karessa Pharma Holding AB (publ) (“Karessa”). The merger between Klaria and Karessa is thereby completed and Karessa has been dissolved.
The SCRO’s registration of the merger completes the merger process from a legal perspective and all of Karessa’s assets and liabilities have been transferred to Klaria. The merged entity will maintain the company name Klaria Pharma Holding AB (publ) and will continue to have its registered office in Stockholm, Sweden.
In connection with the registration of the merger, the SCRO has today registered the issue of 6,635,200 new shares in Klaria as merger consideration. Thus, Klaria has in total 38,728,448 outstanding shares.
Each share in Karessa will be exchanged for 0.6032 new shares in Klaria. Karessa’s shareholders are estimated to receive the Klaria shares, i.e. the merger consideration, on 9 March 2020. Trading in the Klaria share takes place as usual and will not be affected by the merger process.
The nature of this information requires Klaria Pharma Holding AB (publ) to publish it as provided in the Nasdaq First North Growth Markets Rules for Issuers. This information was issued under the supervision of the contact person below for publication on 6 March 2020 at 16:00 CET.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (email@example.com, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.